No currently available test can formally prove that the leukaemic clone is eradicated. Here we discuss the sensitive measurement of minimal residual disease, and speculate on the biology of BCR-ABL-positive cells that may persist after effective therapy of CML. Leukemia (2011) 25, 193-200; doi:10.1038/leu.2010.197; published online 16 September 2010″
“Introduction: No direct proof
has been brought to light in a link between hypoxic changes in glioma models and the effects of antiangiogenic treatments. Here, we assessed the sensitivity of the detection of hypoxia through the use of (18)F-fluoromisonidazole positron emission tomography ([(18)]-FMISO PET) in response to the evolution of the tumor and its vasculature.
Methods: Orthotopic glioma tumors were induced in rats after implantation of C6 or 9L cells. Sunitinib this website was administered from day (D) 17 to D24. At D17 and D24, multiparametric magnetic
resonance imaging was performed to characterize tumor growth and vasculature. Hypoxia was assessed by [(18)F]-FMISO PET.
Results: We showed that brain hypoxic volumes are related to glioma volume and its vasculature and that an antiangiogenic treatment, leading to an increase in cerebral selleck screening library blood volume and a decrease in vessel permeability, is accompanied by a decrease in the degree of hypoxia.
Conclusions: We propose that [(18)F]-FMISO PET and multiparametric magnetic resonance imaging are pertinent complementary tools in the evaluation of the effects of an antiangiogenic treatment in glioma. (C) 2011 Elsevier Inc. All rights reserved.”
“BCR-ABL-targeting tyrosine kinase inhibitors (TKIs) constitute the cornerstone of treatment for chronic myeloid leukemia. Although these agents are normally safe and effective, they can cause side effects that lead to intolerance and necessitate selleck compound switching to an alternative treatment. In this review, we describe side
effects that occur during treatment with imatinib, nilotinib or dasatinib-the currently approved TKI treatments for chronic myeloid leukemia-including class effects and key differences in safety profiles. We also describe how common side effects can be effectively managed and offer a working definition of intolerance that may be useful to clinicians when they consider switching between TKIs. Leukemia (2011) 25, 201-210; doi:10.1038/leu.2010.215; published online 23 September 2010″
“Introduction: Interleukin (IL)-1 and IL-18 are potent proinflammatory cytokines in inflammation-related diseases. Their actions are regulated by IL-1 receptor antagonist (IL-1ra) and IL-18 binding protein (IL-18bp). This study was designed to (99m)Tc-radiolabel an IL-1ra and IL-18bp dual-domain cytokine ligand, IL-18bp-Fc-IL-1ra, for specific inflammation targeting.
Methods: The (99m)Tc-IL-18bp-Fc-IL-1ra was obtained by direct labeling via 2-iminothiolane reduction.